Escherichia coli: development of carbapenem resistance during therapy.

65Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Cite

CITATION STYLE

APA

Hong, T., Moland, E. S., Abdalhamid, B., Hanson, N. D., Wang, J., Sloan, C., … Thomson, K. S. (2005). Escherichia coli: development of carbapenem resistance during therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 40(10). https://doi.org/10.1086/429822

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free